Zacks Investment Research
20 Oct 2026, 15:50 UTC · 1h ago
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
Impact · against what's priced in
The CONNECT study results are positive but fail to act as a catalyst because the market is already pricing in the growth trajectory for Type 2 non-insulin expansion. While the clinical data supports the bull case, the price currently ignores the full volume surge required to hit that target, and a single study does not bridge the gap toward reimbursement and physician adoption.
- DXCM+0.05
Already priced in
- The price assumes
Medicare and commercial PDM coverage for Type 2 non-insulin patients
The 0.9 percentage point A1C reduction over routine care provides the clinical evidence needed for insurance coverage, but the price already assumes the G7 will capture growth in the Type 2 non-insulin market.
What DXCM's price assumes · Sep 23
Top 1 mover · tap to explore
